Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Ottawa

$105,000.00

CD40 ligand as a potential adjuvant for a pan-variant intranasal vaccine against SARS-CoV-2

FY 2023-24

Summary
The COVID-19 pandemic began in December of 2019, following the identification of SARS-CoV-2, an coronavirus with likely zoonotic origins. Vaccination has been instrumental in global efforts to limit the extent of the pandemic, greatly reducing COVID-19-related mortality. Unfortunately, commercial SARS-CoV-2 vaccines have diminished efficacy against emerging variants, necessitating updated vaccine formulations and booster shots. Research into vaccination strategies capable of generating mucosal and variant-proof immunity is critical not only to limit the spread of future SARS-CoV-2 variants, but also for controlling future outbreaks of other viruses. We aim to evaluate the effectiveness of using CD40 ligand, a well-studied vaccine adjuvant, as part of intranasal vaccine formulation against SARS-CoV-2. We will compare the robustness of the vaccine to a traditional intramuscular counterpart, and determine the extent of protection afforded against immune escaping SARS-CoV-2 subvariants. This work will improve our understanding of the mechanisms underlying effective vaccination against SARS-CoV-2, which will be applicable for future emerging respiratory viruses as well.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
497341
Name
Tamming Levi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
CD40 ligand as a potential adjuvant for a pan-variant intranasal vaccine against SARS-CoV-2
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Adjuvants; Antibodies; Covid-19; Immunology; Pandemic; Sars-Cov-2; T Cells; Vaccines
Abstract
The COVID-19 pandemic began in December of 2019, following the identification of SARS-CoV-2, an coronavirus with likely zoonotic origins. Vaccination has been instrumental in global efforts to limit the extent of the pandemic, greatly reducing COVID-19-related mortality. Unfortunately, commercial SARS-CoV-2 vaccines have diminished efficacy against emerging variants, necessitating updated vaccine formulations and booster shots. Research into vaccination strategies capable of generating mucosal and variant-proof immunity is critical not only to limit the spread of future SARS-CoV-2 variants, but also for controlling future outbreaks of other viruses. We aim to evaluate the effectiveness of using CD40 ligand, a well-studied vaccine adjuvant, as part of intranasal vaccine formulation against SARS-CoV-2. We will compare the robustness of the vaccine to a traditional intramuscular counterpart, and determine the extent of protection afforded against immune escaping SARS-CoV-2 subvariants. This work will improve our understanding of the mechanisms underlying effective vaccination against SARS-CoV-2, which will be applicable for future emerging respiratory viruses as well.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Tamming, Levi
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~